The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

The RCTs evaluating these drugs with endocrine therapy for up-front treatment of women with ER+ MBC reported ... who have no overt signs of cancer. Even if administration of a CDK4/6 inhibitor reduces ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

Considering taking supplements to treat aromatase inhibitor induced arthralgia? Below is a list of common natural remedies used to treat or reduce the symptoms of aromatase inhibitor induced ...

NICE has previously backed first-line use of Ibrance in combination with aromatase inhibitor drugs in HR+/HER2- breast cancer, after Pfizer reduced the price of the drug in the wake of an initial ...

Preclinical studies have demonstrated IDE275's (GSK959) potential as a best-in-class WRN inhibitor, inducing single-agent tumor regressions in MSI-H patient-derived xenograft (PDX) and cell line ...

4 IDEAYA/GSK presentations of IDE275 (GSK959) and 4 additional presentations across IDE397/MAT2A, IDE161/PARG, PRMT5, and KAT6/7 programs at AACR 2025 IDE275 (GSK959) has demonstrated a potential ...